Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.22.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
COSTS AND EXPENSES:    
Research and development $ 68,838 $ 36,157
General and administrative 23,474 14,354
  92,312 50,511
Operating loss (92,312) (50,511)
Interest income, net 25 48
Net loss (92,287) (50,463)
Warrant deemed dividend (451)
Preferred stock deemed dividend (1,260)
Net loss available to common stockholders $ (92,287) $ (52,174)
Net loss per common share, basic and diluted $ (0.26) $ (0.55)
Weighted average common shares outstanding, basic and diluted 360,215,323 94,591,715